Praxis Precision MedicinesPRAX
Recorded

Praxis Precision Medicines 3rd Annual Guggenheim Healthcare Innovation Conference

Review the key takeaways and the transcript of this earnings call.

PeriodFY 0Duration27 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Yatin SunejaBiotech Analyst

All right, I think we're live now. Good morning, everyone. Welcome to our third annual, or Guggenheim's third annual Healthcare Innovation Conference. My name is Yatin Suneja, one of the biotech analysts here. Our next presenting company is Praxis. From the company, we have two executives. We have Marcio Souza, who's the Chief Executive Officer, and we also have the Chief Financial Officer, Tim Kelly, here with us. Marcio, I'm going to keep my comments very, very short because there's a lot going on at Praxis. Why don't you maybe talk about what's happening, how are things going. Obviously, you have two NDAs under review, and there's a lot more happening. Why don't you maybe start on the regulatory side from an update perspective, and then we go into some Q&A.

Marcio SouzaCEO

Yeah. Thanks so much. Always great to be here, and thanks for everyone in the room and on the webcast. Two NDAs is not for the faint of hearts, right. I think we talked about that before. You might have read our press release this morning. We intentionally kept very thin, just to be clear on why and two reasons why. One, we're having this conversation right now, which I think is going to be quite important, and then we have the investor day, which I would love for all of you to either show up in New York or tune in for the webcast. The conversations with the FDA, as you would expect, at this point in time, are fairly advanced. I will start with arguably the most important here is ulixacaltamide.

Marcio SouzaCEO

I can say I don't think I could be happier on where we are with those discussions, and it's always nerve-wracking as you're getting towards the end of a process and had a lot of conversations. We always strongly believe the agents understood this application after granting last year, it's almost a year ago now, granting a Breakthrough Therapy Designation for us that they actually understood the unmet needs and the potential that ulixacaltamide hydrochloride has on the lives of these patients coping every day with essential tremor. But it's good to come towards the end and realize that it still holds true on the agent side.

Marcio SouzaCEO

We have completed still the late cycle meeting with the FDA, and I can tell you that in a sense, not that common, but most of the conversations, if not all of the conversations, during the LCM meeting with the agents were about labeling, which our reads of that, notwithstanding that we don't actually control the outcome, of course, at this point in time, was very clearly that the agents really were more working with us towards what is going to be on the label, on the different sections, exposing their thinking about some of those things. I would say for all of you, the questions I get from all of you more recently tends to be titration, tends to be overall view of efficacy.

Marcio SouzaCEO

While I am not going to expand any further on that, what I can say is being fairly aligned with all the conversations we had throughout the last several months, the application has been there. So, it is not possible to have left the building there, the agents, with any other feeling but the one that comes January, you are going to be getting this drug approved and, of course, launching shortly thereafter. Now, with the proper caveats that are making forward-looking statements and they can change, and they are not entirely on our control. So, very, very good. With relutrigine, we had the late cycle, ironically it is called LCM, that is why sometimes I call life cycle, the late cycle meeting there as well. A little behind when you compare with ulixa.

Marcio SouzaCEO

The conversation was a lot more about some recent information requests the agents had to us, some questions they had, discussion open, some of the response we provided. So not quite there in terms of, I think you could, and probably rightly so, think that is an earlier PDUFA, but seems to be a little bit behind in terms of the review cycle or the finalization of the cycle, and I think that would be a proper representation of what happened. If we did not have two, would not be able to compare. I strongly believe both of these drugs are going to be approved as we expected, but it is in a different stage. I would say from the conversations with us, it might be exactly the same stage inside the agents. We just do not have visibility for that. But nothing on those two meetings changed the plans that we had.

Marcio SouzaCEO

Yeah, it is really moving forward with the launch, moving forward with all the prep that we have ahead of us.

Yatin SunejaBiotech Analyst

Got it. Very helpful. These are some really important updates. So, Marcio, you just mentioned end of the process for ulixa twice, and I am surprised you have already completed the LCM or the late-stage meeting, or you have already gone through it. So, I am not going to ask you about the label because I do not think you can comment much. The simple question is, if the FDA acts fast, are you able or how fast can you launch?

Marcio SouzaCEO

Yeah. We're planning to launch, like, today. If we are so blessed, I do not believe this is going to happen before people start including this in the small. If we are so blessed on receive that NDA approval letter, we would just be able to execute the launch, yeah, immediately. One of the points that has been, and you might recall in our mid-cycle, we talked a little bit about that, is whether or not the drug's going to be scheduled, right?

Marcio SouzaCEO

Yeah. We discussed back then that we recommended no scheduling.

Marcio SouzaCEO

The no scheduling is based on a full eight-factor analysis that shows, in our view, that there would be no needs. But I also acknowledge, as we always done, that some of the AEs are ones that historically the agents actually been a little bit more guarded and recommended to HHS and then to DEA for scheduling. I think once again, at this point in time, there were some conversations about that. While we don't have a definitive view on that, it is quite possible, I would say, in my view, that we would have, as we discussed before, and the reason why I'm bringing that up in terms of launch readiness, why we're going to be ready, there's certain things that can be done before the final scheduling, but you cannot commerce, right?

Marcio SouzaCEO

You cannot actually markets on the sense of being able to ship the drug until There is zero impact in the launch. I want to be incredibly clear from the get-go, we've been planning for that scenario. But whether or not we're going to be approved on or before January and be able to ship the drug, or it's going to be a few months before ship the drug, I would say is largely irrelevant for this application, but we're going to be ready either way.

Yatin SunejaBiotech Analyst

Got it. I think it's generally about three months for scheduling. I might be wrong, but I think that's the number.

Yatin SunejaBiotech Analyst

That is correct. You said no impact on the launch, so I would assume, is it the five, which is the least one?

Yatin SunejaBiotech Analyst

Five or four? Correct. Something in that range?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day